This will be our last issue for the next couple of months
with the slowdown of summer now upon us.
It has been a very busy year at LifeSciences BC as we have worked hard to
provide a solid calendar of educational and networking events, engaged in a results
driven advocacy program, while supporting a myriad of international inquires, meetings and collaborations for our growing and impressive world renowned life sciences sector.
We have also welcomed a new President and CEO, Wendy Hurlburt, had a steady rise
in new members, renewed and increased support from our sponsors; without whom would make impossible, our engagement and facilitation of everything that we do.
Our Fall 2019 season is looking just as impressive with
several events already booked and collaborations well underway.
We wish everyone a safe and very relaxing summer and will be back
the second week of September.
Sincerely,
The Team at LifeSciences BC
member
NEWS
DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019
June 25, 2019 |
VANCOUVER, British Columbia and MENLO PARK, Calif., |PRNewswire | -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it has completed the rights offering period and will be extending the subscription period until 5:00 PM Eastern time on July 12, 2019, unless further extended by the Company.
SCN Launches Funding Competition to Support Translational Stem Cell Research Across Canada
June 13, 2019 | Ottawa |
The Stem Cell Network is pleased to launch a new national research funding competition comprised of four translational research programs in stem cell and regenerative medicine. The first round opened today to support innovative research that will ultimately realize both health and economic benefits for Canadians. Over the next three years, SCN anticipates that $11 million will be made available through two peer-reviewed funding competitions.
AbbVie to buy Allergan under deal worth $63 billion
June 25, 2019 |The Wall Street Journal| AbbVie announced Tuesday that it entered into a definitive agreement to acquire Allergan in a cash and stock transaction with an equity value of approximately $63 billion as it looks to reduce its reliance on Humira.
Bristol-Myers Squibb provides update on pending merger with Celgene
Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps
AbbVie keeps May TV focus on Humira, while Gilead spends big on HIV drugs
Pfizer leases Puerto Rico plant to medical marijuana producer
June 26, 2019 | BY: Eric Palmer |
Looks like unloading surplus manufacturing sites to the cannabis industry is turning into a budding business for pharma. At the same time Novartis was negotiating a deal to sell a Colorado plant to a CBD producer, Pfizer was leasing a facility to a medical marijuana supplier.
Lilly enlists patients to raise cluster headache awareness after Emgality scores second nod
June 25, 2019 | BY: Beth Snyder Bulik |
Cluster headache pain is so intense, one patient describes banging his head against the refrigerator door to make it stop. And he's just one of several patients describing the agitating pain of episodic cluster headaches in Eli Lilly's new educational video to raise awareness around the condition.
San Francisco becomes first U.S. city to ban all sales of e-cigarettes
No other U.S. city has brought in such a far-reaching, hardline approach
Jun 25, 2019 | Thomson Reuters | San Francisco will become the first major city in the United States to ban the sale of e-cigarettes as officials look to control the rapid uptick in teenage use of nicotine devices made by companies such as Juul Labs.
New therapy targets gut bacteria to prevent and reverse food allergies
June 24, 2019 | Brigham and Women's Hospital |A new study identifies the species of bacteria in the human infant gut that protect against food allergies, finding changes associated with the development of food allergies and an altered immune response.
We are seeking a highly motivated individual to join our multi-disciplinary team in translating cutting-edge research into novel therapeutics. The candidate will join our biology group and play an integral role in our work to assess new targets and design & implement biochemical assays supporting our preclinical programs. Additional duties may include cloning and protein purification. Alectos offers a competitive compensation and benefits package, including a minimum of 3 weeks vacation. Job Description
Quality Assurance Manager
Did you know that you no longer have to book an appointment with your doctor and wait weeks to get lab results back for STIs like HIV and Syphilis?
bioLytical's INSTI is the world's fastest testing platform - providing results in just 1 minute. Yes, you read that correctly - results in 1 minute not 1 to 2 weeks!
The Supercluster Project Manager is a collaborative member of the Sectors team and works seamlessly across the organization. Reporting to the CSO & VP Sectors, you are the main point of contact at Genome BC for approved Canada's Digital Technology Supercluster (Supercluster) projects and you are responsible for launching, developing and coordinating activities on projects funded under this initiative.
The Data Manager (DM) represents a core functional role for the department and supports the organization and conduct of data management activities for which the department assumes the responsibility for study management.
Evonik stands for attractive business and innovative prowess. Our corporate culture is geared toward results, profitable growth, and increasing the value of the company. Operating in over 100 countries, we benefit from close customer relationships and leading market positions. Over 36,000 employees are united by the understanding that no product is so perfect that you can't make it better.
Dear BioLinks Subscribers
IN THIS ISSUE
